Filtered By:
Condition: Diabetes
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 723 results found since Jan 2013.

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
Introduction The world is undergoing a demographic transition to an older population. Preventive healthcare has reduced the burden of chronic illness at younger ages but there is limited evidence that these advances can improve health at older ages. Statins are one class of drug with the potential to prevent or delay the onset of several causes of incapacity in older age, particularly major cardiovascular disease (CVD). This paper presents the protocol for the STAtins in Reducing Events in the Elderly (STAREE) trial, a randomised double-blind placebo-controlled trial examining the effects of statins in community dwelling o...
Source: BMJ Open - April 3, 2023 Category: General Medicine Authors: Zoungas, S., Curtis, A., Spark, S., Wolfe, R., McNeil, J. J., Beilin, L., Chong, T. T.-J., Cloud, G., Hopper, I., Kost, A., Nelson, M., Nicholls, S. J., Reid, C. M., Ryan, J., Tonkin, A., Ward, S. A., Wierzbicki, A., On behalf of STAREE investigator group Tags: Open access, Cardiovascular medicine Source Type: research

Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: A high-resolution MRI study
This study aimed to determine the effects of PCSK9i on intracranial plaques in moderate-intensity statin-treated individuals with ICAS.METHODS: This prospective, observational study monitored the imaging and clinical outcomes of individuals with ICAS who were consecutively treated with moderate-intensity statins with or without PCSK9i. Individuals underwent monthly visits and repeat high-resolution MRI (HR-MRI) at week 12. The primary outcome was a change in HR-MRI after 12 weeks of treatment and the secondary outcome was major vascular events during follow-up.RESULTS: Forty-nine individuals were studied (PCSK9i group: 26 ...
Source: Atherosclerosis - March 27, 2023 Category: Cardiology Authors: Lingshan Wu Qianqian Kong Hao Huang Shabei Xu Wensheng Qu Ping Zhang Zhiyuan Yu Xiang Luo Source Type: research

Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota. Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research

Atherosclerotic patients with diabetes mellitus may break through the threshold of healthy TMAO levels formed by long-term statins therapy
CONCLUSION: Diabetics have abnormally high plasma TMAO levels even under continuous statins treatment, which may contribute to the development and progression of atherosclerosis. Therefore, it is necessary to focus on monitoring TMAO levels in diabetic patients to reduce adverse cardiovascular events in diabetic patients.PMID:36879744 | PMC:PMC9984437 | DOI:10.1016/j.heliyon.2023.e13657
Source: Atherosclerosis - March 7, 2023 Category: Cardiology Authors: Hao Liang Anqi Yu Zheng Wang Na Zhang Qingsong Wang Haichao Gao Junhui Gao Xinjun Wang Hong Wang Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - March 1, 2023 Category: Drugs & Pharmacology Source Type: research

Does aspirin have a place in primary cardiovascular prevention by the polypill  ? Simulation study on a realistic virtual population
CONCLUSION: Until proven otherwise, aspirin has only a limited place in individuals between 35 and 65 years without a cardiovascular history. We showed how simulating therapeutic strategies on a realistic virtual population could be used for best applying available evidence.PMID:36841655 | DOI:10.1016/j.therap.2023.01.011
Source: Therapie - February 25, 2023 Category: Psychiatry & Psychology Authors: Mor Fall Guillaume Grenet Hai-Ha Le Behrouz Kassa ï Jean-Christophe Lega R émy Boussageon Sabine Mainbourg Ivanny Marchant Johanne Gafsi Amadou Moctar Dieye Fran çois Gueyffier Source Type: research

Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
CONCLUSIONS: Statins appear to be generally well-tolerated in kidney transplant recipients. However, statin use might be associated with slightly higher risk of post-transplant diabetes mellitus, cataract, and rhabdomyolysis.PMID:36800538 | DOI:10.2215/CJN.0000000000000124
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 17, 2023 Category: Urology & Nephrology Authors: Sunjae Bae JiYoon B Ahn Kmd Corey Joseph Ryan Whisler Mark A Schnitzler Krista L Lentine Bernard S Kadosh Dorry L Segev Mara A McAdams-DeMarco Source Type: research